A 31-year-old woman is evaluated in the emergency department for severe nausea, vomiting, … — USMLE Step 2 CK

A $31$ -year-old woman is evaluated in the emergency department for severe nausea, vomiting, diffuse muscle aches, and profound restlessness. She has a history of severe opioid use disorder. For the past three years, she has been maintained on a daily dose of $80\text{ mg}$ of methadone. Two days ago, her physician decided to transition her to sublingual buprenorphine-naloxone to provide more flexible outpatient management. She was instructed to wait until she felt withdrawal symptoms before taking her first dose. She took her last dose of methadone approximately $36$ hours ago. One hour ago, she took her first prescribed dose of sublingual buprenorphine-naloxone. Vital signs show a temperature of $37.2^\circ\text{C}$ ( $99.0^\circ\text{F}$ ), blood pressure of $158/96\text{ mm Hg}$ , pulse of $118\text{/min}$ , and respirations of $18\text{/min}$ . Physical examination reveals dilated pupils, excessive lacrimation, rhinorrhea, and piloerection. The patient's skin is clammy, and she is visibly shivering. She reports, "I thought this new medication was supposed to help, but I feel worse than I ever have." Which of the following is the most likely primary mechanism responsible for this patient's acute symptom presentation?

Displacement of a full agonist by a partial agonist with higher receptor affinityCevap
B
Systemic absorption of an opioid receptor antagonist through the sublingual mucosa
C
Uncoupling of the mu-opioid receptor from its associated G-proteins due to rapid tolerance
D
Rebound sympathetic discharge secondary to spontaneous clearance of a long-acting opioid
E
Synergistic activation of central serotonergic pathways leading to autonomic instability

Cevap

The mechanism is the displacement of a full agonist (methadone) by a partial agonist (buprenorphine) that has a higher affinity for the mu-opioid receptor.

This patient is experiencing precipitated opioid withdrawal. Buprenorphine is a partial mu-opioid receptor agonist with very high receptor affinity—significantly higher than that of full agonists like methadone or heroin. When buprenorphine is administered to a patient who still has a full agonist occupying their receptors, the buprenorphine aggressively displaces the full agonist. Because buprenorphine has a lower intrinsic efficacy (as a partial agonist), the net opioid effect at the receptor abruptly drops. This sudden, steep decrease in opioid stimulation triggers severe withdrawal symptoms. Methadone has a prolonged half-life, meaning a significant amount remained in her system at

36

hours. Transitioning from methadone to buprenorphine requires specialized protocols (such as cross-tapering or micro-dosing) to avoid this exact complication.

Adım Adım Çözüm

Identify the patient's clinical syndrome.

The patient is experiencing acute opioid withdrawal (mydriasis, piloerection, rhinorrhea, nausea, myalgias, tachycardia).

Vital signs and physical exam findings are classic for an adrenergic surge secondary to lack of opioid receptor stimulation.

Correlate the symptom onset with the timeline of medications.

The symptoms began explosively exactly one hour after the first dose of buprenorphine-naloxone, administered 36 hours after her last methadone dose.

Methadone has a very long half-life (

24

130

hours). Significant levels of methadone were still occupying her mu-opioid receptors at

36

hours.

Apply the pharmacodynamics of the administered medication.

Buprenorphine is a partial mu-opioid agonist with a very high binding affinity.

Because its affinity is higher than methadone's, it tightly binds to the receptors, rapidly displacing the remaining methadone.

Determine the net effect on the receptor.

The displacement of a full agonist (methadone) by a partial agonist (buprenorphine) causes a sudden, steep drop in overall mu-opioid receptor activation, precipitating severe withdrawal.

This is the classic presentation of precipitated withdrawal, which requires careful clinical management during transitions.

Anahtar Kavram

Buprenorphine is a partial mu-opioid receptor agonist with a higher binding affinity than most full agonists. Administering it to a patient with a full agonist still on their receptors will cause rapid displacement, leading to a net decrease in opioid effect and precipitated withdrawal.

Tahmini Süre:1m 30s

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru